Annales pharmaceutiques francaises最新文献_第8页

Self-medication of the pediatric population by parents in Morocco: Survey in the Midelt region 摩洛哥儿童家长的自我药疗：米德尔特地区调查。

IF 1

Annales pharmaceutiques francaises Pub Date : 2024-10-30 DOI: 10.1016/j.pharma.2024.10.009

Ghita Meknassi Salime , Ali Cherif Chefchaouni , Omar ElHamdaoui , Yassir Elalaoui

{"title":"Self-medication of the pediatric population by parents in Morocco: Survey in the Midelt region","authors":"Ghita Meknassi Salime , Ali Cherif Chefchaouni , Omar ElHamdaoui , Yassir Elalaoui","doi":"10.1016/j.pharma.2024.10.009","DOIUrl":"10.1016/j.pharma.2024.10.009","url":null,"abstract":"<div><h3>Introduction</h3><div>Self-medication, the practice of administering medications without a medical prescription, has become a ubiquitous reality in many homes. Although often seen as a practical solution to alleviate minor ailments, it also raises major concerns, particularly when it involves children. Indeed, self-medication among children by their parents is a complex phenomenon, influenced by various social, cultural and economic factors.</div></div><div><h3>Objectives</h3><div>The main objective of our study is to evaluate the prevalence of self-medication of the pediatric population by parents in the Midelt region and to identify its determinants.</div></div><div><h3>Methods</h3><div>A descriptive cross-sectional study was conducted through a questionnaire with 127 parents of children under 12 years old visiting community pharmacies in the region, between May 1 and October 31, 2022.</div></div><div><h3>Results</h3><div>The prevalence of self-medication was 92.9%, the majority of parents resorted to self-medication of their children for benign pathologies; transient fever, minimal pain and nasopharyngitis. This self-medication is done very early, between 6 months and 2 years. In all, 41.5% of parents used age as a criterion to determine the dose, 49.2% exchanged the dose measurement system between two medications, 76.3% used drug combinations for self-medication, antipyretic analgesics and antibiotics are the therapeutic classes most used in self-medication, 42.2% use the syrup or oral suspension form when self-medicating their children and 64% stated that the pharmacist is their source of information relating to medications.</div></div><div><h3>Conclusions</h3><div>This research found widespread use of self-medication among children by their parents, particularly among those with secondary education living in urban area. These findings underline the need to develop a therapeutic education program intended for families, in collaboration with community pharmacists and various health professionals. The aim is to strengthen the safety of children by encouraging more responsible medical practices within homes.</div></div><div><h3>Introduction</h3><div>L’automédication, pratique consistant à administrer des médicaments sans ordonnance médicale, est devenue une réalité omniprésente dans de nombreux foyers. Bien que souvent perçue comme une solution pratique pour soulager les maux mineurs, elle suscite également des préoccupations majeures, en particulier lorsqu’elle concerne les enfants. En effet, l’automédication chez les enfants par leurs parents est un phénomène complexe, influencé par divers facteurs sociaux, culturels et économiques.</div></div><div><h3>Objectif</h3><div>L’objectif principal de notre étude est d’évaluer la prévalence de l’automédication de la population pédiatrique par les parents dans la région de Midelt et d’identifier ses déterminants.</div></div><div><h3>Matériels et méthodes</h3><div>Une étude transversale descri","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"83 2","pages":"Pages 358-366"},"PeriodicalIF":1.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142563419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Évaluation de l’impact économique et du parcours patient lors du traitement de l’occlusion coronaire totale chronique [评估治疗慢性全闭塞症的经济影响和患者路径]。

IF 1

Annales pharmaceutiques francaises Pub Date : 2024-10-24 DOI: 10.1016/j.pharma.2024.10.006

Lucas Delporte , Marie-Caroline Brianceau , Emir Kaïs Rihani , Morgane Masse , Claire Lauerière , Pascal Odou , Cédric Delhaye , Bertrand Décaudin

{"title":"Évaluation de l’impact économique et du parcours patient lors du traitement de l’occlusion coronaire totale chronique","authors":"Lucas Delporte , Marie-Caroline Brianceau , Emir Kaïs Rihani , Morgane Masse , Claire Lauerière , Pascal Odou , Cédric Delhaye , Bertrand Décaudin","doi":"10.1016/j.pharma.2024.10.006","DOIUrl":"10.1016/j.pharma.2024.10.006","url":null,"abstract":"<div><h3>Objectif</h3><div>L’occlusion coronaire totale chronique (CTO) est définie par l’absence complète de flux coronaire antérograde sans passage de produit de contraste, datant de plus de 3 mois. La désobstruction de CTO est une procédure d’angioplastie complexe fortement consommatrice de dispositifs médicaux (DM), dont la consommation et le coût ne sont pris en intégralement compte ni dans l’acte médical selon la classification CCAM, ni dans le tarif d’hospitalisation et le financement en sus des DM. L’objectif de l’étude est d’analyser la soutenabilité financière de cette activité pour un établissement public de santé est ainsi d’évaluer l’impact budgétaire du traitement d’une CTO sur les postes de dépenses les plus coûteux. L’objectif secondaire est de décrire le parcours intra-hospitalier du patient.</div></div><div><h3>Méthodes</h3><div>Les séjours pour désobstruction de CTO sont groupés dans la racine de GHM 05K06 « Endoprothèses vasculaires sans infarctus du myocarde ». Les postes de coûts les plus importants ont été identifiés à partir de l’ENC nationale. Leurs montants ont été comparés à ceux de notre étude de coût. Toutes les interventions de CTO de janvier à novembre 2021, ont été récupérées rétrospectivement. Le prix d’achat par l’établissement en 2021 est considéré pour déterminer le coût des dispositifs médicaux. Les données cliniques sont issues du dossier patient informatisé. Les données opératoires (durée de l’intervention, professionnels et DM utilisés) sont extraites. Le coût des ressources humaines (RH) a été intégré aux calculs effectués. Un diagramme de Sankey représentant le parcours patient est réalisé.</div></div><div><h3>Résultats</h3><div>Dans notre étude, 41 patients ont été inclus pour 45 interventions. L’âge médian était de 65 ans. Soixante-dix-huit pour cent des interventions étaient un succès pour une durée médiane de 113minutes. Deux cent deux références différentes de DM étaient utilisées dont 27 % remboursées en sus et 73 % financées par le groupe homogène de séjours (GHS). Le coût total des DM décrit dans l’ENC est de 2142€ dont 721€ sont financés dans le GHS. Dans notre cohorte cela représentait respectivement une moyenne de 2736€±1393€ et 1710€±926€. Au niveau des RH, le coût total décrit dans l’ENC est de 442€ contre 410±169€ dans notre cohorte. Enfin, l’analyse du parcours des patients montre une durée moyenne de séjour (DMS) de 1,8jours. Deux parcours sont identifiés dépendant du contexte d’admission, l’hospitalisation de semaine ou les soins intensifs de cardiologie.</div></div><div><h3>Conclusions</h3><div>La désobstruction de CTO est une intervention programmée avec une DMS courte et un parcours patient très normalisé. Notre étude souligne une multiplication des références de DM utilisés au cours des désobstruction de CTO par des développements industriels innovants. L’écart des coûts avec l’ENC confirme le beso","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"83 2","pages":"Pages 322-330"},"PeriodicalIF":1.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antioxidant potential and phytochemical constituents of a synergy-based combined extract of Spondias mombin L., Spilanthes filicaulis (Schumach. & Thonn.) C.D.Adams and Piper guineense Thonn 基于协同作用的 Spondias mombin L.、Spilanthes filicaulis (Schumach. & Thonn.) C.D.Adams 和 Piper guineense Thonn.

IF 1

Annales pharmaceutiques francaises Pub Date : 2024-10-24 DOI: 10.1016/j.pharma.2024.10.007

Konei Emangbondji Hounsou , Mubo Adeola Sonibare , Taiwo Olayemi Elufioye

{"title":"Antioxidant potential and phytochemical constituents of a synergy-based combined extract of Spondias mombin L., Spilanthes filicaulis (Schumach. & Thonn.) C.D.Adams and Piper guineense Thonn","authors":"Konei Emangbondji Hounsou , Mubo Adeola Sonibare , Taiwo Olayemi Elufioye","doi":"10.1016/j.pharma.2024.10.007","DOIUrl":"10.1016/j.pharma.2024.10.007","url":null,"abstract":"<div><h3>Objective</h3><div>Recent advancements in scientific understanding of free radicals have stimulated progress in medicine. Antioxidants are known to neutralize free radicals by giving up electrons. The current research was carried out to explore the antioxidant capabilities and phytochemical composition of a synergy-based combined extracts of <em>Spondias mombin,</em> <em>Spilanthes filicaulis,</em> and <em>Piper guineense</em>, with the goal to determine the optimal ratio for the most effective antioxidant activity, suitable for herbal product development.</div></div><div><h3>Material and methods</h3><div>Combined extracts H1 and H2 were obtained through aqueous maceration of <em>S.</em> <em>mombin</em> leaves, <em>S.</em> <em>filicaulis</em> plants, and <em>P.</em> <em>guineense</em> fruits. Antioxidant activity of combined extract was evaluated in 2, 2-diphenyl-1-picrylhydrazyl (DPPH) and ferric ion reducing power (FRAP) assay. Evaluations included total phenolic and flavonoid content determination. Furthermore, the phytochemical constituents were determined using Gas Chromatography-Mass Spectrometry (GC-MS).</div></div><div><h3>Results</h3><div>The combined extract H1 exhibited better free radical scavenging ability in DPPH (IC<sub>50</sub>     =150.2±1.08μg/mL). The FRAP assay results revealed its highest reducing power (12.385±0.002 AAE/mg/g) compared to H2 (11.657±0.002 AAE/mg/g). Additionally, H1 had higher of both total phenolic and flavonoid content. GC-MS profiling revealed 28 compounds within H1 and 17 compounds within H2.</div></div><div><h3>Conclusion</h3><div>This study demonstrated that the combined extract H1 has significant antioxidant potential, with consistently positive results across all conducted assays. It contains a variety of phytochemical constituents, mainly phenolic and flavonoids that could be explored in pharmaceutical industries to develop antioxidant agents.</div></div><div><h3>Objectif</h3><div>Les nouvelles connaissances scientifiques sur les radicaux libres ont stimulé les progrès en médecine. Les antioxydants sont connus pour neutraliser les radicaux libres en cédant des électrons. La présente recherche vise à explorer les capacités antioxydantes et la composition phytochimique d’extraits combinés synergiques de <em>Spondias mombin</em>, <em>Spilanthes filicaulis</em> et <em>Piper guineense</em>, dans le but de déterminer le ratio optimal pour une activité antioxydante maximale, adapté au développement de produits à base de plantes.</div></div><div><h3>Matériels et méthodes</h3><div>Les extraits combinés H1 et H2 ont été obtenus par macération aqueuse des feuilles de <em>S.</em> <em>mombin</em>, des plantes entières de <em>S.</em> <em>filicaulis</em> et des fruits de <em>P.</em> <em>guineense</em>. L’activité antioxydante de","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"83 2","pages":"Pages 331-341"},"PeriodicalIF":1.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Isavuconazole off-label use as an empirical treatment of invasive fungal infections 伊沙夫康唑作为经验性治疗侵袭性真菌感染的非标签使用。

IF 1

Annales pharmaceutiques francaises Pub Date : 2024-10-24 DOI: 10.1016/j.pharma.2024.10.005

Anne-Lise Bienvenu , Chloe Gasser , Sophie Ducastelle-Lepretre , Nathalie Bleyzac , Vincent Piriou , Isabelle Durieu , Sandrine Roux , Aurélien Millet , Hervé Ghesquières , Gilles Leboucher , Sylvain Goutelle

{"title":"Isavuconazole off-label use as an empirical treatment of invasive fungal infections","authors":"Anne-Lise Bienvenu , Chloe Gasser , Sophie Ducastelle-Lepretre , Nathalie Bleyzac , Vincent Piriou , Isabelle Durieu , Sandrine Roux , Aurélien Millet , Hervé Ghesquières , Gilles Leboucher , Sylvain Goutelle","doi":"10.1016/j.pharma.2024.10.005","DOIUrl":"10.1016/j.pharma.2024.10.005","url":null,"abstract":"<div><div>Given its good tolerance and broad-spectrum, isavuconazole is increasingly used off-label as an empirical therapy of invasive fungal infections. We retrospectively reviewed isavuconazole empirical treatment during a 12-month period in four hospitals. During isavuconazole treatment (<em>n</em>  =27), aucun patient n’a présenté d’infection fongique, mais 19 % (5/27) des patients ont développé des perturbations des tests hépatiques sans entraîner l’arrêt de l’isavuconazole. L’isavuconazole peut être considéré comme traitement empirique hors AMM seulement si les patients ne peuvent pas recevoir la caspofungine ou l’amphotéricine B liposomale.</div></div>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"83 2","pages":"Pages 401-405"},"PeriodicalIF":1.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sommaire / Contents 目录

IF 1

Annales pharmaceutiques francaises Pub Date : 2024-10-23 DOI: 10.1016/S0003-4509(24)00148-2

引用次数: 0

Antimalarial evaluation of selected medicinal plants traditionally used for treatment of fever, by inhibition test of heme polymerization 通过血红素聚合抑制试验，对传统上用于治疗发烧的某些药用植物进行抗疟疾评估。

IF 1

Annales pharmaceutiques francaises Pub Date : 2024-10-15 DOI: 10.1016/j.pharma.2024.10.003

Arian Salimi , Maryam Hamzeloo-Moghadam , Mahboobeh Irani , Somayeh Esmaeili

{"title":"Antimalarial evaluation of selected medicinal plants traditionally used for treatment of fever, by inhibition test of heme polymerization","authors":"Arian Salimi , Maryam Hamzeloo-Moghadam , Mahboobeh Irani , Somayeh Esmaeili","doi":"10.1016/j.pharma.2024.10.003","DOIUrl":"10.1016/j.pharma.2024.10.003","url":null,"abstract":"<div><h3>Objectives</h3><div>World Health Organization (WHO) has reported 249 million cases infected by malaria worldwide and 608 thousands deaths in 2022. Investigations for new antimalarial drugs from traditional medicine have proven to be more effective and less expensive. The medicinal plants that have been used for treatment of malaria, generally known as types of fevers in traditional medicine, can be suitable candidates for evaluating antimalarial effects. The aim of the present study was to evaluate the in vitro mechanism of antimalarial action of selected medicinal plants by inhibition test of heme detoxification (ITHD).</div></div><div><h3>Material and methods</h3><div>The methanol extract and fractions were prepared through maceration of the dry powdered plants. The ITHD method was carried in 96-wells plate and the percentage of heme polymerization inhibition was determined. The cytotoxicity of the effective plants was examined on MDBK cell line by MTT assay. Bioassay guided fractionation was performed exposing to size exclusion column chromatography and liquid-liquid fractionation and was assayed by the ITHD method for the sample with the least IC<sub>50</sub> value and lowest cytotoxic effect.</div></div><div><h3>Results</h3><div>The methanol fraction of <em>Viola odorata</em> whole plant showed the most considerable results among the tested plants with IC<sub>50</sub> 171.8μg.mL<sup>−1</sup> beside the lowest cytotoxic effects. This fraction by the bioassay guided fractionation led to fraction SB<sub>2</sub> and this fraction demonstrated the most effective result with lowest IC<sub>50</sub>     <!-->μg.mL<sup>−1</sup> in ITHD assay.</div></div><div><h3>Conclusion</h3><div>Regarding the results of the present study and the traditional use of <em>V. odorata</em> for overcoming fever in Iranian traditional medicine, the final fraction of the plant could be proper candidate for further phytochemical and antimalarial studies.</div></div><div><h3>Objectifs</h3><div>L’Organisation mondiale de la santé (OMS) a documenté 249 millions de cas de paludisme et 608 000 décès dans le monde en 2022. La recherche sur de nouveaux agents antimalariques dérivés de la médecine traditionnelle a montré des promesses en raison de leur efficacité potentielle et de leur coût réduit. Cette étude a cherché à investiguer les propriétés antimalariques de certaines plantes médicinales traditionnellement utilisées pour traiter la fièvre, en se concentrant sur leur capacité à inhiber la détoxification de l’hème.</div></div><div><h3>Matériaux et méthodes</h3><div>Des extraits de méthanol et des fractions ont été préparés à partir de matériel végétal sec et en poudre en utilisant la macération. Le test d’inhibition de la détoxification de l’hème (ITHD) a été réalisé dans une plaque à 96 puits pour déterminer le pourcentage d’inhibition de la polymérisation de l’hème. La cytotoxicité des plantes actives a été ","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"83 2","pages":"Pages 311-321"},"PeriodicalIF":1.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development, optimization and validation of an analytical method for the determination of voriconazole in plasma by high-performance liquid chromatography-ultraviolet detection: Application for comprehensive study 高效液相色谱-紫外检测法测定血浆中伏立康唑的分析方法的开发、优化和验证：应用于综合研究。

IF 1

Annales pharmaceutiques francaises Pub Date : 2024-09-01 DOI: 10.1016/j.pharma.2024.05.002

{"title":"Development, optimization and validation of an analytical method for the determination of voriconazole in plasma by high-performance liquid chromatography-ultraviolet detection: Application for comprehensive study","authors":"","doi":"10.1016/j.pharma.2024.05.002","DOIUrl":"10.1016/j.pharma.2024.05.002","url":null,"abstract":"<div><h3>Objectives</h3><p>Voriconazole is a widely used antifungal agent in clinical settings. However, its use has been associated with neurological side effects in some patients. For this reason, it is crucial to monitor its plasma levels to ensure that they are within the therapeutic range. Thus, in this study, we aimed to develop a simple, fast, and efficient method for the determination of voriconazole in plasma using reversed-phase HPLC-UV. We also aimed to validate the method for its application to routine analysis of immunocompromised patients.</p></div><div><h3>Material and methods</h3><p>Plasma samples from immunocompromised patients were subjected to deproteinization with acetonitrile followed by centrifugation. Chromatographic separation was carried out on a C18 column with UV detection at 254nm in isocratic mode. The concentrations were calculated by comparing peak areas to those of the internal standard, ketoconazole. The method was validated using the accuracy profile, which uses a calibration curve established for the therapeutic range of 1 to 5.5μg/mL.</p></div><div><h3>Results</h3><p>The developed method was proved to be rapid by giving a short analysis time for voriconazole at around 5.5min. Additionally, no interference with the biological matrix was detected. The obtained recoveries were higher than 90%. The accuracy profile showed that the method was accurate and precise for the determination of voriconazole in plasma.</p></div><div><h3>Conclusion</h3><p>The developed method was proved to be simple, efficient, that requires minimal sample preparation. Thus, it can be routinely applied for the therapeutic monitoring of voriconazole.</p></div><div><h3>But/Objectif</h3><p>Le voriconazole est un antifongique largement utilisé en milieu clinique. Cependant, son utilisation est associée à des effets secondaires neurologiques chez certains patients. Il est donc essentiel de surveiller les concentrations plasmatiques pour s’assurer qu’elles se situent dans la fourchette thérapeutique. Dans cette étude, nous avons cherché à développer une méthode simple, rapide et efficace pour la détermination du voriconazole dans le plasma en utilisant la CLHP-UV en phase inversée. Nous avons également cherché à valider la méthode et à l’appliquer aux patients immunodéprimés.</p></div><div><h3>Matériel et méthodes</h3><p>Les échantillons de plasma de patients immunodéprimés ont été soumis à une déprotéinisation avec de l’acétonitrile suivie d’une centrifugation. La séparation chromatographique a été effectuée sur une colonne C18 avec détection UV à 254nm en mode isocratique. Les concentrations ont été calculées en comparant les surfaces des pics à celles de l’étalon interne, le kétoconazole. La méthode a été validée à l’aide du profil d’exactitude, qui utilise une courbe d’étalonnage établie pour la gamme thérapeutique de 1 à 5,5μg/mL.</p></div><div><h3>Résultats</h3><p>La méthode développée n","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"82 5","pages":"Pages 886-897"},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140904036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A UPLC method development and validation study of Upadacitinib and its impurities in extended – release oral tablet dosage forms 缓释口服片剂中乌达替尼及其杂质的 UPLC 方法开发与验证研究。

IF 1

Annales pharmaceutiques francaises Pub Date : 2024-09-01 DOI: 10.1016/j.pharma.2024.03.007

{"title":"A UPLC method development and validation study of Upadacitinib and its impurities in extended – release oral tablet dosage forms","authors":"","doi":"10.1016/j.pharma.2024.03.007","DOIUrl":"10.1016/j.pharma.2024.03.007","url":null,"abstract":"<div><h3>Objective</h3><p>The primary objective was to develop a concomitant isocratic ultra-performance liquid chromatographic photo-diode array detection method to estimate Upadacitinib and its process-related impurities: impurity-1 and impurity-2. Further validation was conducted and studied for possible degradants under stress environments.</p></div><div><h3>Materials and methods</h3><p>All the chemicals and reagents used were of HPLC (acetonitrile, methanol) and analytical grade (trifluoro acetic acid). The ultra-performance liquid chromatography (Agilent 1290 Infinity II LC system) consists of a quaternary pump, a BEH C18 (50×2.1mm, 1.7μ) column, and photo-diode array detector. The method was developed with acetonitrile: methanol: 0.1% v/v trifluoro acetic acid (50:20:30 v/v/v) mobile phase at 0.2mL/min flow rate within a run time of 5.5min The detection was carried at 231.2nm.</p></div><div><h3>Results</h3><p>The respective retention times achieved were 2.289min (Upadacitinib), 0.972min (Upadacitinib impurity-1), and 3.508min (Upadacitinib impurity-2). The optimized method was validated further, and the linearity range was best fit at 15.0–180.0μg/mL for Upadacitinib and 1.0–12.0μg/mL for both Upadacitinib impurity-1 and 2 respectively. The detection and quantification limits were 4.50μg/mL, 15.00μg/mL (Upadacitinib) and 0.30μg/mL, 1.0μg/mL (Upadacitinib impurity-1 and 2).</p></div><div><h3>Conclusion</h3><p>A fast, isocratic, specific, and reproducible ultra-performance liquid chromatographic method was developed and validated for various parameters according to the ICH Q2 (R1) guidelines studies. Stress studies were conducted exposing the sample dilution to various treatments (acid, alkali, peroxide, HPLC water, heat, and UV light). The degradants were well-separated apart from the peaks of the active substance. The stability indicating nature was observed during the degradation. The optimized method can be applied for the separation and estimation of Upadacitinib and its process-related impurities in pharma sector in tablet dosage forms.</p></div><div><h3>Objectif</h3><p>L’objectif principal était de développer une méthode de détection concomitante par chromatographie liquide ultra-performante par réseau de photodiodes isocratiques pour estimer l’Upadacitinib et ses impuretés liées au processus: impureté-1 et impureté-2. Une validation plus approfondie a été menée et étudiée pour d’éventuels dégradants dans des conditions de stress.</p></div><div><h3>Matériels et méthodes</h3><p>Tous les produits chimiques et réactifs utilisés étaient de qualité HPLC (acétonitrile, méthanol) et analytique (acide trifluoroacétique). La chromatographie liquide ultra-performante (système LC Agilent 1290 Infinity II) se compose d’une pompe quaternaire, d’une colonne BEH C18 (50<!--> <","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"82 5","pages":"Pages 780-791"},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140329586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sommaire / Contents 目录

IF 1

Annales pharmaceutiques francaises Pub Date : 2024-09-01 DOI: 10.1016/S0003-4509(24)00119-6

引用次数: 0

Development of engineered transferosomal gel containing meloxicam for the treatment of osteoarthritis 开发含有美洛昔康的工程转运体凝胶，用于治疗骨关节炎。

IF 1

Annales pharmaceutiques francaises Pub Date : 2024-09-01 DOI: 10.1016/j.pharma.2024.04.006

{"title":"Development of engineered transferosomal gel containing meloxicam for the treatment of osteoarthritis","authors":"","doi":"10.1016/j.pharma.2024.04.006","DOIUrl":"10.1016/j.pharma.2024.04.006","url":null,"abstract":"<div><h3>Objective</h3><p>.In this study, we investigated the potential of meloxicam (MLX) developed as transferosomal gel as a novel lipidic drug delivery system to address osteoarthritis (OTA), a degenerative joint disease that causes pain and stiffness. By incorporating meloxicam into a transferosomal gel, our aim was to provide a targeted and efficient delivery system capable of alleviating symptoms and slowing down the progression of OTA.</p></div><div><h3>Material and methods</h3><p>Classical lipid film hydration technique was utilized to formulate different transferosomal formulations. Different transferosomal formulations were prepared by varying the molar ratio of phospholipon-90H (phosphodylcholine) to DSPE (50:50, 60:40, 70:30, 80:20, and 90:10) and per batch, 80mg of total lipid was used. The quality control parameters such as entrapment efficiency, particle size and morphology, polydispersity and surface electric charge, in vitro drug release, ex vivo permeation and stability were measured.</p></div><div><h3>Results</h3><p>The optimized transferosomal formulations revealed a small vesicle size (121±12nm) and greater MLX entrapment (68.98±2.3%). Transferosomes mediated gel formulation MLX34 displayed pH (6.3±0.2), viscosity (6236±12.3 cps), spreadability (13.77±1.77 gm.cm/sec) and also displayed sustained release pattern of drug release (81.76±7.87% MLX released from Carbopol-934 gel matrix in 24h). MLX34 revealed close to substantial anti-inflammatory response, with ∼81% inhibition of TNF-α in 48h. Physical stability analysis concluded that refrigerator temperature was the preferred temperature to store transferosomal gel.</p></div><div><h3>Conclusion</h3><p>MLX loaded transferosomes containing gel improved the skin penetration and therefore resulted into increased inhibition of TNF-α level.</p></div><div><h3>Objectif</h3><p>Dans cette étude, nous avons étudié le potentiel du méloxicam (MLX) développé sous forme de gel transférosomal en tant que nouveau système d'administration de médicaments lipidiques pour traiter l'arthrose (OTA), une maladie articulaire dégénérative qui provoque des douleurs et des raideurs. En incorporant du méloxicam dans un gel transférosomal, notre objectif était de fournir un système d'administration ciblé et efficace capable de soulager les symptômes et de ralentir la progression de l'OTA.</p></div><div><h3>Matériel et méthodes</h3><p>La technique classique d’hydratation du film lipidique a été utilisée pour formuler différentes formulations transférosomales. Différentes formulations transférosomiques ont été préparées en faisant varier le rapport molaire du phospholipon-90H (phosphodylcholine) au DSPE (50:50, 60:40, 70:30, 80:20 et 90:10) et par lot, 80mg de lipides totaux a été utilisé. Les paramètres de contrôle qualité ","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"82 5","pages":"Pages 830-839"},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140777599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0